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Abstract
Purpose Adenocarcinoma of the salivary glands is of low incidence and a broad range of histopathological subtypes. Cancer 
stem cell markers (CSC) might serve as novel prognostic parameters. To date, only a few studies examined the expression 
of CSC in adenocarcinoma of the salivary glands with diverging results. To further investigate the reliability in terms of 
prognostic value, a histopathological analysis of CSCs on a cohort of patients with adenocarcinomas of the major salivary 
glands was performed.
Methods Tumor samples of 40 consecutive patients with adenocarcinoma of the major salivary gland treated with curative 
intend at one tertiary center were stained with the CSCs ALDH1, BMI-1, CD44, Nanog, and SOX2. Expression of these 
markers was correlated with clinicopathological parameters and survival estimates.
Results Correlation of high expression of ALDH1 with higher grading (p < 0.001) and high expression of CD44 with the 
localization of the neoplasm (p = 0.05), larger tumor size (p = 0.006), positive pN-category (p = 0.023), and advanced UICC 
stage (p = 0.002) was found. Furthermore, high expression of SOX2 correlated with a negative perineural invasion (p = 0.02). 
No significant correlation of any investigated marker with survival estimates was observed.
Conclusion In conclusion, our study did not find a significant correlation of the investigated CSCs with survival estimates 
in adenocarcinoma of the major salivary glands. Recapitulating the results of our study in conjunction with data in the lit-
erature, the CSCs ALDH1, BMI-1, CD44, Nanog, and SOX2 do not seem to serve as reliable prognostic parameters in the 
treatment of adenocarcinoma of the salivary glands.
Keywords Salivary glands · Adenocarcinoma · Prognostic marker · Cancer stem cell markers · CSC · Salivary gland 
malignoma
Introduction
Malignoma of the salivary glands exhibits a low incidence 
of 2.5–3.0 cases per 100,000 people per year [1]. Together 
with a broad range of more than 20 histological subtypes, 
and different localization, the investigation of this disease 
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seems challenging [2]. However, a multimodal treatment-
regimen with radical resection of the tumour, neck dis-
section, and adjuvant radiotherapy is recommended, and 
has shown superior survival in comparison to resection 
alone [3]. Clinical parameters like histopathological entity, 
grading, tumour size, and perineural invasion have proven 
helpful to estimate prognosis in malignoma of the sali-
vary glands [4]. In cases of recurrence or inoperability, 
treatment options are limited and mostly chemotherapy in 
terms of a palliative care setting remain [5]. With a disease 
so rare combined with a possibly poor prognosis, further 
investigations about the pathogenesis of those tumour enti-
ties is required to improve treatment concepts.
Cancer stem cells are known to exhibit infinite prop-
erties of self-renewal, reconstitution of tumour-heteroge-
neity and maintenance of tumour growth [6]. Since the 
discovery of cancer stem cells, the involvement of certain 
markers as key regulators in oncologic diseases has been 
investigated thoroughly throughout the past decades [7]. 
In the head and neck region, cancer stem cell markers 
(CSC) are suspected to play a role in oncogenesis, as well 
as progression and prognosis of the disease [8]. ALDH1 
serves as a marker for both tissue-resident stem cells, as 
well as cancer stem cells of different tissue types [9], like 
lung, colon, prostate, pancreatic, endometroid cancer, and 
head and neck malignoma [10]. BMI-1 is an epigenetic 
key regulator and influences p53 and Rb proteins, and 
was found to function as an enhancer for self-renewal in 
hematopoietic stem cells [11], head and neck tumours, and 
breast adenocarcinomas [12]. CD44 is known as a pivotal 
marker for cancer stem cells, and an overexpression in 
cancer cells with a suspected exhibition of highly malig-
nant and therapeutic resistance properties is reported [13]. 
Also, a correlation of CD44 overexpression in head and 
neck squamous cell cancer (HNSCC) was observed [14]. 
The cancer stem cell marker Nanog serves as a marker for 
pluripotency in both tissue-resident and cancer stem cells 
and plays a role in maintaining pluripotency [15]. Nanog 
is reported to correlate with a promotion of metastasis 
and poor prognosis in HNSCC [16]. SOX2, together with 
Nanog, is a transcription factor associated with the main-
tenance of stem cell pluripotency [17]. A correlation with 
an aggressive feature is reported in colon cancer, breast 
cancer, and HNSCC [18].
Evaluation of expression of those markers in malignoma 
of the salivary glands exists only in a few studies so far, 
which have shown diverging results in correlation with clin-
icopathological parameters and survival estimates. Thus, the 
question arises how reliable those CSCs could be in terms 
of a prognostic parameter. Therefore, we performed a histo-
pathological analysis on a cohort of patients with adenocar-
cinomas of the major salivary glands to gain further insights 
into the promising novel prognostic parameter.
Material and methods
Patients and compliance with ethical standards
Retrospective analysis of 132 consecutive patients treated 
for epithelial malignoma of the salivary glands at one ter-
tiary referral centre, the Department of Otorhinolaryngol-
ogy, University Medical Centre Göttingen, Georg-August 
University Göttingen, Germany from 2003 to 2015. 
Patients treated primarily by surgery in curative intent, 
and in which an adenocarcinoma of the parotid or subman-
dibular gland was diagnosed pathologically, were included 
in the analysis (Fig. 1a). 40 patients fulfilled those criteria. 
The analysis included patients’ and disease characteristics, 
as well as survival-rates.
The study protocol was performed according to the ethi-
cal guidelines of the 2002 Declaration of Helsinki and car-
ried out after approval by the Institutional Review Board 
and Ethics Committee of the University Medical Centre 
Göttingen (reference number 2/1/17). All patients gave 
written consent to the study.
Immunohistochemistry
After assembly of 40 haematoxylin and eosin-stained 
slides into a tissue-microarray paraffin block, one-mil-
limetre thick sections were cut and immunohistochemi-
cally (IHC) stained. Sections were dewaxed with clearify 
clearing agent (Agilent, Hamburg, Germany) for 20 min 
at 65 °C and blocked with EnV FLEX Peroxidase-Block-
ing Reagent (Agilent, Hamburg, Germany) for 15 min at 
97 °C. IHC staining for ALDH-1 (1:200 FLEX + Rabbit, 
ABCAM, Cambridge, United Kingdom), BMI-1 (1:200 
FLEX + Rabbit, CellSignalling, Leiden, Netherlands), 
Nanog (1:12,800 FLEX + Mouse, CellSignalling, Leiden, 
Netherlands) and CD44 (1:50 FLEX, CellSignalling, Lei-
den, Netherlands) was performed with the AutostainerLink 
48 (Dako, Hamburg, Germany), incubated for 30 min at 
room temperature (RT) and incubated another 15 min at 
RT with the marked polymer EnV FLEX/HRP (Agilent, 
Hamburg, Germany). The reaction was developed by 
adding the diaminobenzidine FLEX/DAB + Substrate-
Chromogene (Agilent, Hamburg, Germany) and counter-
stained with haematoxylin (Agilent, Hamburg, Germany) 
for 3 min at RT. IHC staining with SOX2 (FLEX + Rab-
bit, Cell Marque, California, USA) was performed with 
the Dako Omnis (Dako, Hamburg, Germany). Prior to 
IHC staining with SOX2, the samples were dewaxed with 
Clearify Clearing Agent for 1 min at 25 °C. Demasking 
was performed by applying EnV FLEX TRS for 30 min 
at 97 °C. Then, the antibody for SOX2 was added and 
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incubated for 20 min. For blocking, the samples were incu-
bated with EnV FLEX Peroxidase-Blocking for 3 min. As 
an enhancer EnV FLEX + Rabbit LINKER was applied. 
The reaction was developed by adding diaminobenzidine 
FLEX/DAB + Substrat-Chromogene and then counter-
staining with haematoxylin. Between each step, the sam-
ples were washed with a buffer solution.
H-score was applied for assessing the extent of immu-
noreactivity with the following formula:
3 × percentage of strongly staining membrane/cyto-
plasm/nuclei + 2 × percentage of moderately staining 
membrane/cytoplasm/nuclei + percentage of weakly stain-
ing membrane/cytoplasm/nuclei, giving a range of 0–300 
[19]. The H-Score was used by the two examiners in our 
pathology department. Diverging results were discussed 
between both examiners.
Calculation of a cutoff-value to define the high or low 
expression of the markers were performed with a ROC-
curve and Youden-Index with the program easyROC ver-
sion 1.3 [20]. Cutoff-values of the markers were as the 
following: BMI-1 cutoff at 190; CD44 cutoff at 255; SOX2 
cutoff at 30. For calculation of ALDH1 and Nanog lack 
of staining was considered as a low expression. The clus-
tering heat map was generated via the software Cluster, 
version 3.0 (Stanford University, Stanford, USA; https ://
www.encod eproj ect.org/softw are/clust er/).
Statistical analysis
Statistical analysis was performed with the software Sta-
tistica, version 13.1 (StatSoft Europe, Hamburg, Germany) 
with values statistically significant at p < 0.05. Statistical 
differences between groups were calculated by the log-
rank test and Mann–Whitney-U test. Overall survival (OS), 
disease-specific-survival (DSS), recurrence-free-survival 
(RFS) and the local control-rate (LCR) were calculated 
starting from the date of primary surgery by application 
of the Kaplan–Meier method. Calculating OS, death for 
any reason was considered as an event, and patients alive 
at last follow-up were censored. Regarding DSS, events 
were defined as death related to the primary tumour alone, 
and other causes of death were considered as censored. 
Concerning RFS, local and/or regional recurrences, dis-
tant metastasis or death-related to primary diagnosis were 
considered as events. Whereas, intercurrent-death or death 
related to secondary primaries, and patients alive without 
any disease-manifestation accounted for censored obser-
vations. In LCR, local recurrences were considered as 
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Carcinoma ex pleomorphic carcinoma
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131 received surgical treatment
(92 AC, 39 SCC)
110 patients pathologically verified AC or SCC of the major salivary glands
(71 AC, 39 SCC)
99 patients primary disease in the major salivary glands
(66 AC, 33 SCC)
86 patients treated at the same tertiary referral center
(55 AC,  31 SCC) 
40 patients with AC in the major salivary glands
132 patients with malignant disease of the major salivary glands
(92 AC, 40 SCC)
71 patient samples for analysis in the archive of the pathology department
(40 AC, 31 SCC) 
Fig. 1    Inclusion criteria and subtypes of adenocarcinomas. a 40 
patients with adenocarcinoma of the major salivary glands, who 
received surgical treatment at one tertiary centre were included in 
the study. b 9 different entities of adenocarcinoma were summarized 
as adenocarcinoma of the major salivary glands, listed in a descend-
ing order regarding their share of patients (%). AC, adenocarcinoma; 
SCC, squamous cell cancer
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events. Correlation of expression of CSCs with clinico-
pathological data was performed by the chi-square test and 
odds ratio. In the present study three- and 5 year estimates 
are presented. For multivariate analysis, we used logistic 
regression to evaluate the effect of clinicopathological 
variables. To avoid overfitting, we restricted ourselves to 
fitting clinicopathological variables that had the smallest 
p values in the single variable analysis or were deemed 
potentially biologically relevant. The model was fitted 
using the package glm with the software R (Build 3.2.5 




Mean age was 64.4 ± 16.9  years, follow-up was 
41.8 ± 42.0 months. Different histopathological subtypes 
were summarized as adenocarcinomas and are depicted in 
Fig. 1b. 50% (n = 20) were staged a T1-2 tumour, and 52.5% 
(n = 21) did not exhibit a locoregional metastasis at the time 
of diagnosis. 52.5% (n = 21) had a G2-graded adenocarci-
noma, and in 90% (n = 36) of the patients a R0-resection 
was reached. Regarding treatment, 50% (n = 20) received 
the resection of the tumour along with a neck dissection 
and postoperative radiotherapy. A subset of 15 patients 
(37.5%) received a resection of the tumour with neck dis-
section, thereof in 10 patients an indication for postoperative 
radiotherapy was declined by the tumour board, two patients 
rejected this adjuvant therapy, and in three the radiother-
apy was aborted due to complication issues. Three patients 
received tumour resection alone, of which in one patient no 
adjuvant therapy was recommended by the interdisciplinary 
tumour board, and the other two patients rejected the postop-
erative radiotherapy, as well as a following salvage surgical 
treatment. Two patients received a resection of the tumour 
with postoperative radiotherapy. All data regarding patients 
and disease characteristics are depicted in Table 1.
Immunohistochemistry
The complete cohort was analysed for high or low expres-
sion of the CSC ALDH1, BMI-1, CD44, Nanog, and SOX2. 
BMI-1 was highly expressed in 52.5% (n = 21) of the cohort, 
CD44 in 30% (n = 12). In terms of expression of ALDH1, 
Nanog, and SOX2, most of the cohort showed a low expres-
sion. Detailed data are shown in Table 1. Exemplary immu-
nohistochemical staining for low and high expression is 
depicted in Fig. 2a–e.
Correlation of patient and disease characteristics 
with CSC
Concerning an association of CSCs with clinicopathologi-
cal parameters, a strong correlation of ALDH1 expression 
and higher histopathological grading (G1 vs. G2-3) was 
observed (p < 0.001). Expression of CD44 significantly 
correlated with the localization of the neoplasm (parotid 
vs. submandibular gland; p = 0.050), a larger tumour size 
(T1-2 vs. T3-4; p = 0.006), positive N-category (p = 0.023), 
and advanced UICC stage III-IV (p = 0.002). Regarding a 
high expression of SOX2, a significant association with a 
negative perineural invasion was observed (p = 0.020). In 
terms of BMI-1 and Nanog, no correlation was shown within 
this cohort (Table 2). To find a correlation upon patient and 
disease characteristics, a hierarchical clustering heat map 
was performed (Supplemental Fig. 1). By generating the 
heat map, two groups were identified: Group 1 contained 
tumour samples with high expression of BMI-1/CD44, and 
low expression of ALDH1/Nanog/SOX2, which correlated 
significantly with a higher grading (G1 vs. G2/3; p = 0.029). 
Group 2 was characterised by tumour samples exhibiting low 
expression of BMI-1/CD44 and high expression of ALDH1/
Nanog/SOX2 associated with a lower grading (Supplemental 
Table 1). Results of the corresponding multivariate analysis 
are displayed in Supplemental Table 2.
Correlation of patient and disease characteristics 
and CSC with survival rates
Three- and 5 year survival-estimates (OS, DSS, RFS, LCR) 
were correlated with patient and disease characteristics, as 
well as expression of CSC (Table 3). Concerning histopatho-
logical grading, significant differences in both three- and 
5 year survival rates between G1-2 and G3 with regard to OS 
(5 year-estimates: 87.0 vs. 20.2%; p < 0.001), DSS (5 year-
estimates: 100.0 vs. 38.1%; p < 0.001), and RFS (5 year 
estimates: 83.3 vs. 40.5%; p = 0.043) were seen. Compari-
son of UICC stages showed a significant difference in RFS 
between UICC I-II and UICC III-IV (5 year-estimates: 90.0 
vs. 61.9%; p = 0.030). Overall, no statistically significant 
differences were found regarding survival rates of high and 
low expression of the examined CSCs. Same findings were 
observed in the results of hierarchical clustering (Supple-
mental Table 3).
Discussion
The current study found no significant differences in sur-
vival-rates with regard to the investigated CSCs BMI-1, 
CD44, ALDH-1, Nanog, and SOX2. Concerning a corre-
lation with disease characteristics, an association of high 
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expression of ALDH1 with grading, high expression of 
CD44 with localization of the neoplasm, T- and N-cate-
gory, and UICC stage, as well as high expression of SOX2 
with perineural invasion was observed. Regarding IHC, 
the cohort of adenocarcinoma of the major salivary glands 
showed a predominantly high expression of BMI-1. Signifi-
cant lower survival-estimates correlated with a high-grade 
histopathological disease.
Since salivary gland malignoma is a rather rare entity [1], 
clinicopathological data is scarce. To date, only 9 studies 
Table 1   Patient and Disease Characteristics with Expression of Cancer Stem Cell Markers
CT chemotherapy, n, number of cases, ND neck dissection, Pn perineural invasion, R margin status, RT radiotherapy, TNM tumor, nodal metasta-
sis, UICC International Union Against Cancer (7th edition)





 Parotid gland 28 70























 Surgical tumor resection 3 7.5
 Surgical tumor resection + ND 15 37.5
 Surgical tumor resection + RT 2 5
 Surgical tumor resection + ND + RT 20 50
Recurrence 10 25
Expression of cancer stem cell markers Low expression High expression
n % n %
ALDH1 36 90 4 10
BMI-1 19 47.5 21 52.5
CD44 28 70 12 30
Nanog 36 90 4 10
SOX2 33 82.5 7 17.5
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Fig. 2   Immunohistochemi-
cal staining with low and high 
expression of the cancer stem 
cell markers ALDH1, BMI-1, 
CD44, Nanog, and SOX2. (a) 
Immunostaining with ALDH1: 
low expression (left; × 10) in a 
ductal adenocarcinoma, high 
expression (right; × 10) in an 
adenoidcystic carcinoma. (b) 
Immunostaining with BMI-
1: low expression (left; × 20) 
in an adenocarcinoma, high 
expression (right; × 20) in a 
salivary duct carcinoma. (c) 
Immunostaining with CD44: 
low expression (left; × 40) in 
a salivary duct carcinoma, 
high expression (right; × 20) 
in an adenocarcinoma. (d) 
Immunostaining with Nanog: 
low expression (left; × 20) in a 
mucoepidermoid carcinoma, 
high expression (right; × 20) in 
a mucoepidermoid carcinoma. 
(e) Immunostaining with SOX2: 
low expression (left; × 20) in a 
mucoepidermoid carcinoma, 
high expression (right; × 20) 
in a polymorphous low-grade 
adenocarcinoma
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have examined the prognostic value of CSCs in adenocarci-
noma of the major and minor salivary glands (Table 4). Our 
study is the only one so far to evaluate the correlation of the 
markers ALDH1, BMI-1, CD44, Nanog, and SOX2 with 
survival-rates and clinicopathological data in adenocarci-
noma of the major salivary glands. The limitations lie in the 
retrospective nature and small evaluated cohort of the study. 
To apply a sound statistical comparison, higher numbers 
would be preferable.
The cohort of the present study consists of a compa-
rable sample size when looking at other studies which 
analysed CSCs in adenocarcinomas of the salivary glands 
[21, 22]. Concerning the distribution of patients and dis-
ease characteristics, the data of our study is in line with 
the literature, where a large cohort of 4068 patients with 
malignoma of the salivary glands from the National Can-
cer Database (NCDB) of the American Cancer Society 
and Commission on Cancer of the American College of 
Surgeons was investigated with regard to postoperative 
radiotherapy on survival-estimates [3].
In terms of ALDH1, an association of low expres-
sion with higher histopathological grading was observed. 
Zhou et al. observed a high ALDH1-expression in stromal 
cells of their cohort of 216 patients with adenoidcystic 
carcinoma; however, a significant correlation to survival-
estimates was not found [23]. Sun et al. showed a high 
correlation of high ALDH-1-levels in adenoidcystic car-
cinoma with higher tumorigenic, invasive, and metastatic 
properties [24]. Regarding other tumour entities, diverging 
results in terms of a prognostic parameter were found. For 
example, in endometroid cancer higher ALDH1-expres-
sion correlated with longer overall and disease-free sur-
vival [25]; whereas, the study group around Chen et al. 
reported of a positive correlation of ALDH1 expression 
with a negative outcome in HNSCC [10].
Table 2   Correlation of patient and disease characteristics with the expression of cancer stem cell markers
G grading, N nodal status, Pn perineural invasion, T tumor size, UICC International Union Against Cancer (7th edition)
ALDH1 BMI-1 CD44 Nanog SOX2
Low High p 
value
Low High p value Low High p value Low High p value Low High p value
Sex
 Female 9 2 0.288 5 6 0.873 9 2 0.315 10 1 0.906 8 3 0.479
 Male 27 2 14 15 19 10 26 3 24 5
Age
  < 60 years 14 3 0.166 7 10 0.491 11 6 0.530 16 1 0.455 12 5 0.201
  ≥ 60 years 22 1 12 11 17 6 20 3 20 3
Localization
 Parotid gland 25 3 0.818 14 14 0.629 17 11 0.050 24 4 0.168 23 5 0.605
 Submandibular gland 11 1 5 7 11 1 12 0 9 3
Grading
 G1/2 25 4 0.194 12 17 0.208 22 7 0.189 26 3 0.906 21 8 0.051
 G3 11 0 7 4 6 5 10 1 11 0
Grading
 G1 4 4  < 0.001 5 3 0.342 7 1 0.227 8 0 0.292 6 2 0.693
 G2/3 32 0 14 18 21 11 28 4 26 6
pT-category
 T1–T2 17 3 0.292 16 4 0.288 18 2 0.006 19 1 0.292 17 3 0.429
 T3–T4 19 1 13 7 10 10 17 3 15 5
pN-category
 Negative 18 3 0.342 12 9 0.199 18 3 0.023 20 1 0.246 18 3 0.342
 Positive 18 1 7 12 10 9 16 3 14 5
Perineural invasion
 Pn0 22 4 0.122 13 13 0.666 18 8 0.885 25 1 0.077 18 8 0.020
 Pn1 14 0 6 8 10 4 11 3 14 0
UICC stage
 I–II 11 3 0.077 8 6 0.370 14 0 0.002 13 1 0.658 13 1 0.136
 III–IV 25 1 11 15 14 12 23 3 19 7
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Regarding BMI-1, our cohort exhibited a high expression 
in half of the cases, without correlation to neither survival-
estimates nor clinicopathological parameters. Yi et al. found 
a high correlation of metastatic disease with expression 
of BMI-1 in a cohort of 102 patients with adenoid cystic 
carcinoma [26]. Whereas Destro Rodrigues et al. did not 
observe any correlation to survival-estimates or prognos-
tic parameters [27]. Concerning other cancer entities, pre-
viously Koren et al. found a low expression of BMI-1 in 
96 advanced staged non-small cell lung cancer (NSCLC) 
Table 3   Correlation of patient and disease characteristics and expression of cancer stem cell markers with survival Rates
DSS disease-specific survival, G grading, LCR local control rate, n number of cases, N N-category, OS overall survival, RFS recurrence-free sur-
vival, RT radiotherapy, T tumor size, UIC, International Union Against Cancer, 7th edition;
n OS (%) DSS (%) RFS (%) LCR (%)
3 years 5 years p value 3 years 5 years p value 3 years 5 years p value 3 years 5 years p value
Complete cohort 40 71.3 65.8 82.4 82.4 71.9 71.9 84.6 84.6
Sex
 Female 11 88.9 88.9 0.138 100.0 100.0 0.130 87.5 87.5 0.497 87.5 87.5 0.648
 Male 29 64.4 58.0 75.5 75.5 66.1 66.1 83.7 83.7
Age
  < 60 years 18 76.5 76.5 0.195 8.3 81.3 0.752 75.6 75.6 0.778 86.7 86.7 0.557
  ≥ 60 years 22 66.2 49.6 83.6 83.6 68.5 68.5 83.1 83.1
Primary location
 Parotid gland 28 59.7 59.7 0.730 74.5 74.5 0.099 63.8 63.8 0.062 77.3 77.3 0.094
 Submandibular gland 12 100.0 85.7 100.0 100.0 90.0 90.0 100.0 100.0
Histological grading
 G1–2 29 95.7 87.0  < 0.001 100.0 100.0  < 0.001 83.3 83.3 0.043 87.5 87.5 0.421
 G3 11 20.2 20.2 38.1 38.1 40.5 40.5 75.0 75.0
T-category
 T1–T2 20 85.9 73.7 0.298 91.7 9.7 0.142 79.8 79.8 0.139 93.8 93.8 0.166
 T3–T4 20 58.1 58.1 73.7 73.7 64.9 64.9 75.7 75.7
N-category
 N0 21 77.7 77.7 0.330 82.1 82.1 0.978 82.3 82.3 0.146 94.1 94.1 0.075
 N + 19 63.1 52.6 82.5 82.5 57.2 57.2 71.9 71.9
UICC stage
 UICC I–II 14 82.5 82.5 0.355 90.0 90.0 0.326 90.0 90.0 0.030 100.0 100.0 0.067
 UICC III–IV 26 65 56.9 78.5 78.5 61.9 61.9 75.6 75.6
Postoperative radiotherapy
 RT + 22 71.7 63.7 0.299 82.5 82.5 0.405 68.3 68.3 0.286 89.1 89.1 0.051
 RT − 6 41.7 41.7 50.0 50.0 37.5 37.5 37.5 37.5
ALDH1
 High 4 100.0 100.0 0.159 100.0 100.0 0.254 100.0 100.0 0.165 100.0 100.0 0.326
 Low 36 67.1 61.0 79.4 79.4 67.7 67.7 82.4 82.4
BMI-1
 High 21 87.4 77.7 0.051 87.4 87.4 0.400 72.7 72.7 0.972 84.0 84.0 0.841
 Low 19 54.1 54.1 77.4 77.4 72.0 72.0 84.8 84.8
CD44
 High 12 75.0 75.0 0.690 81.8 81.8 0.814 63.6 63.6 0.231 71.6 71.6 0.145
 Low 28 67.5 57.8 82.1 82.1 75.1 75.1 91.1 91.1
Nanog
 High 4 66.7 0.936 66.7 0.473 50.0 0.217 75.0 0.498
 Low 36 71.6 66.1 84.2 84.2 74.5 74.5 85.5 85.5
SOX2
 High 7 100.0 75.0 0.184 100.0 100.0 0.192 71.4 71.4 0.613 83.3 83.3 0.854
 Low 33 64.1 64.1 77.6 77.6 72.5 72.5 84.8 84.8
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in comparison to their control group of healthy individu-
als. Furthermore, they observed a correlation of high 
BMI-1 with longer progression-free and overall survival in 
advanced NSCLC patients [28]. Also, an association with 
high BMI-1-expression was observed in breast cancer, mela-
noma, gastric cancer, and nasopharyngeal carcinoma [12, 
29]. CD44 showed a low expression in the majority of our 
carcinoma, mucoepidermoid-carcinoma, and other types of 
adenocarcinoma as investigated in our cohort [21, 27, 30, 
31]. Regarding survival-estimates, we did not observe any 
correlation with CD44 when tested alone. Concerning an 
association with clinical parameters, a correlation with the 
tumour localization, tumour size, nodal status, and prognos-
tic UICC stage was observed. Since CD44 is recognized as 
a pivotal marker for the cancer stem cells [13], a correlation 
with malignant clinicopathological characteristics and the 
worse prognosis seems consistent. The group of Xu et al. 
observed a strong correlation with a significantly increased 
overall survival in patients showing high expression of 
CD44, CD133, and SOX2 combined either all together, or 
CD44 with one of the other both markers. An association 
of one of the three markers alone with clinicopathological 
data was not observed [31]. In contrast, Soave and collabo-
rators tested CD44 combined with CD24 in adenocarcino-
mas of the salivary glands, and found a strong correlation 
with tumour size and lymph node metastasis [21]. Wang 
et al. observed a strong correlation of high CD44-expression 
with distant metastasis, histologic pattern, perineural-inva-
sion, vascular-invasion, and clinical stage [32]. Regarding 
HNSCC, diverging results were described. An older study 
by Mack and Gires specifically investigated the expression 
pattern of CD44 variants (CD44s and CD44v6) in HNSCC, 
and found no difference between benign and malignant tis-
sue [33]. Whereas several recent studies observed a high 
expression of CD44 [34–36]. Concerning other tumour enti-
ties, the CD44 expression and its prognostic significance are 
well-studied, e.g. in breast cancer, colorectal cancer, and 
endometroid cancer [37, 38].
Investigating Nanog, our cohort showed a predominantly 
low expression with no significant correlation upon survival-
rates or clinicopathological parameters. Solely a trend to 
a positive perineural-invasion was observed. Two other 
studies showed similar results investigating patients with 
adenoidcystic or mucoepidermoid-carcinoma [23, 31]. In 
contrast, Destro Rodrigues and collaborators observed a high 
expression of Nanog correlated with a perineural-invasion in 
patients with mucoepidermoid-carcinoma [27]; an associa-
tion with survival-estimates was not observed. Investigations 
of other tumour entities showed promising prognostic values 
of Nanog in endometrioid carcinoma [37], liver cancer, lung 
cancer, and HNSCC [18].
In our cohort, SOX2 showed a low expression with no cor-
relation to survival-estimates. Regarding clinicopathological 
parameters, an association with a negative perineural sta-
tus was observed. Other studies found a high expression of 
SOX2 together with a correlation with clinical staging. Xu 
et al. did not observe any correlations when analysing SOX2 
alone. However, a high expression of SOX2 in combination 
with CD44/CD133 showed a significant lower OS [31]. Dai 
and co-workers found a significant correlation of high SOX2 
expression with advanced T-category, distant metastasis, 
OS, and DFS in patients with adenoidcystic carcinoma [39]. 
Sedassari et al. found an association with T-category, distant 
metastasis, grading, recurrence rate, and adverse outcome in 
their cohort of 30 patients with carcinoma ex-pleomorphic 
adenoma [40]. In terms of other tumour entities, a prognostic 
correlation of SOX2 in colon cancer [41], breast cancer [42], 
and HNSCC [3] is well-documented.
The expression of stem cell markers such as ALDH1, 
BMI-1, CD44, Nanog, and SOX2 is well-investigated for 
other tumour entities, and has shown promising results as 
prognostic parameters with potential as a target for cancer 
treatment [43, 44]. Malignoma of the salivary glands is 
rare per se, with rather worse prognosis [1]. Retrospective 
analyses in literature have found clinical staging as a main 
prognostic factor [4, 21, 45]. Clinical prospective studies 
do not exist due to the low incidence of the disease. Regard-
ing clinicopathological studies, 9 studies investigated a 
correlation of certain CSCs with survival-rates and clinical 
stages to date (Table 4). Unfortunately, the heterogeneity 
of cohorts, applied methods, and investigated CSCs differ 
significantly, therefore, a sound conclusion of those diverg-
ing results seems impossible. Regarding the results of our 
study and the literature, the CSCs ALDH1, BMI-1, CD44, 
Nanog, and SOX2 seem not to serve as reliable prognostic 
parameters in adenocarcinomas of the salivary glands.
Conclusion
In conclusion, our study found no significant correlation 
of the investigated CSCs ALDH1, BMI-1, CD44, Nanog, 
and SOX2 with survival-estimates in adenocarcinoma 
of the major salivary glands. However, observed were a 
high ALDH1-expression associated with higher grading, a 
high CD44-expression with localization of the neoplasm, 
advanced pT- and pN-category, and UICC-stage, as well as 
a high SOX2-expression with negative perineural invasion.
Recapitulating the results of our study in conjunction 
with the literature, the CSCs ALDH1, BMI-1, CD44, Nanog, 
and SOX2 do not seem to serve as reliable novel prognostic 
parameters in the treatment of adenocarcinoma of the sali-
vary glands.
Acknowledgements The authors are indebted to the sup-
port and work of Stefan Küffer, PhD (Department of Pathology, 
European Archives of Oto-Rhino-Laryngology 
1 3
Georg-August-University of Goettingen, Goettingen, Germany) for 
performing and analysing the histological sections. We are grateful to 
all patients and clinical colleagues who donated or collected clinical 
samples.
Author’s contributions Jennifer L. Spiegel analysed and interpreted 
data, and wrote the paper. Mark Jakob conceptualized the study, 
designed the experiments and provided critical revision. Marie Kruiz-
enga performed experiments, collected and analysed data, and provided 
critical revision. Saskia Freytag performed additional statistical analy-
ses. Mattis Bertlich, Martin Canis, Friedrich Ihler, and Frank Haubner 
interpreted data and provided critical revision. Julia Kitz performed 
experiments, interpreted data, and provided critical revision. Bern-
hard G. Weiss conceptualized the study, designed the experiments, 
collected, analysed and interpreted data, and provided critical revision. 
All authors discussed the results and implications and commented on 
the manuscript at all stages.
Funding Open Access funding enabled and organized by Projekt 
DEAL.
Data availability Original data are available on demand.
Code availability Statistical analysis was performed with the software 
Statistica, version 13.1 (StatSoft Europe, Hamburg, Germany). The 
respective codes are available on demand.
Compliance with ethical standards 
Conflicts of interest The authors declare that they have no conflict of 
interest.
Ethical approval Study protocol was performed according to ethical 
guidelines of the 2002 Declaration of Helsinki and carried out after 
approval by the Institutional Review Board and Ethics Committee of 
the University Medical Centre Göttingen (reference number 2/1/17). 
All patients gave written consent to the study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Barnes L, Eveson J, Reichart P, Sidransky D (2005) Tumours of 
the salivary glands. In: World Health Organization Classification 
of Tumours. Pathology and Genetics of Head and Neck Tumours. 
IARC Press, Lyon, France,
 2. Leivo I (2006) Insights into a complex group of neoplastic disease: 
advances in histopathologic classification and molecular pathol-
ogy of salivary gland cancer. Acta Oncol 45(6):662–668
 3. Safdieh J, Givi B, Osborn V, Lederman A, Schwartz D, Schreiber 
D (2017) Impact of adjuvant radiotherapy for malignantsalivary 
gland tumors. Otolaryngol Head Neck Surg 157(6):988–994
 4. Guzzo M, Locati L, Prott F, Gatta G, McGurk M (2010) Major 
and minor salivary gland tumors. Crit Rev Oncol Hematol 
74(2):134–148
 5. Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rifi H, Raies 
H, Mezlini A (2012) Systemic therapy in the management of 
metastatic or advanced salivary gland cancers. Head Neck Oncol 
4(1):19
 6. Reya T, Morrison S, Clarke M, Weissman I (2001) Stem cells, 
cancer, and cancer stem cells. Nature 414(6859):105–111
 7. Nguyen L, Vanner R, Dirks P, Eaves C (2012) Cancer stem cells: 
an evolving concept. Nat Rev Cancer 12(2):133–143
 8. Prince M, Sivanandan R, Kaczorowski A, al. e, (2007) Identifica-
tion of a subpopulation of cells with cancer stem cell properties 
in head and neck squamous cell carcinoma. Proceedings of the 
National Acadamy of Sciences of the United States of America 
104(3):973–978
 9. Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional 
marker of cancer stem and progenitor cells. Stem Cells Dev 
18(1):17–25. https ://doi.org/10.1089/scd.2008.0055
 10. Chen Y, Chen Y, Hsu H, Tseng L, Huang P, Lu K, Chen D, Tai 
L, Yung M, Chang S, Ku H, Chiou S, Lo W (2009) Aldehyde 
dehydrogenase 1 is a putative marker for cancer stem cells in 
head and neck squamous cancer. Biochem Biophys Res Commun 
385(3):307–313. https ://doi.org/10.1016/j.bbrc.2009.05.048
 11. Park I, Qian D, Kiel M, Becker M, Pihalja M, Weissman I, Morri-
son S, Clarke M (2003) Bmi-1 is required for maintenance of adult 
self-renewing haematopoietic stem cells. Nature 423(6937):302–
305. https ://doi.org/10.1038/natur e0158 7
 12. Paranjape A, Balaji S, Mandal T, Krushik E, Nagaraj P, Mukherjee 
G, Rangarajan A (2014) Bmi1 regulates self-renewal and epithelial 
to mesenchymal transition in breast cancer cells through Nanog. 
BMC Cancer 14:785. https ://doi.org/10.1186/1471-2407-14-785
 13. Toole B (2009) Hyaluronan-CD44 interactions in cancer: para-
doxes and possibilities. Clin Cancer Res 15(24):7462–7468
 14. Joshua B, Kaplan M, Doweck I, Pai R, Weissman I, Prince M, 
Ailles L (2012) Frequency of cells expressing CD44, a head and 
neck cancer stem cell marker: correlation with tumor aggressive-
ness. Head Neck 34(1):42–49. https ://doi.org/10.1002/hed.21699 
 15. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Taka-
hashi K, Maruyama M, Maeda M, Yamanaka S (2003) The home-
oprotein Nanog is required for maintenance of pluripotency in 
mouse epiblast and ES cells. Cell 113(5):631–642
 16. Chiou S, Yu C, Huang C, Lin S, Liu C, Tsai T, Chou S, Chien 
C, Ku H, Lo J (2008) Positive correlations of Oct-4 and Nanog 
in oral cancer stem-like cells and high-grade oral squamous cell 
carcinoma. Clin Cancer Res 14(13):4085–4095. https ://doi.
org/10.1158/1078-0432.CCR-07-4404
 17. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le 
Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, 
Salmon I, Dubois C, del Marmol V, Fuks F, Beck B, Blanpain C 
(2014) SOX2 controls tumour initiation and cancer stem-cell func-
tions in squamous-cell carcinoma. Nature 511(7508):246–250. 
https ://doi.org/10.1038/natur e1330 5
 18. Baillie R, Tan S, Itinteang T (2017) Cancer stem cells in oral cav-
ity squamous cell carcinoma: a review. Front Oncol 7:112. https 
://doi.org/10.3389/fonc.2017.00112 .eColl ectio n2017 
 19. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa 
T, Sunamori M, Handa M, Kondo T, Sasano H (2003) Sex steroid 
hormone receptors in human thymoma. J Clin Endocrinol Metab 
88(5):2309–2317
 20. Goksuluk D, Korkmaz S, Zararsiz G, Karaağaoğlu A (2016) easy-
ROC: an interactive web-tool for ROC curve analysis using R 
language environment. The R Journal 8(2):213–230
 European Archives of Oto-Rhino-Laryngology
1 3
 21. Soave D, Oliveira da Costa J, da Silveira G, Ianez R, de 
Oliveira L, Lourenço S, Ribeiro-Silva A (2013) CD44/CD24 
immunophenotypes on clinicopathologic features of salivary 
glands malignant neoplasms. Diagn Pathol 8:29. https ://doi.
org/10.1186/1746-1596-8-29
 22. Destro Rodrigues M, Sedassari B, Esteves C, de Andrade N, 
Altemani A, de Sousa S, Nunes F (2017) Embryonic stem cells 
markers Oct4 and Nanog correlate with perineural invasion in 
human salivary gland mucoepidermoid carcinoma. J Oral Pathol 
Med 46(2):112–120. https ://doi.org/10.1111/jop.12449 
 23. Zhou J, Hanna E, Roberts D, Weber R, Bell D (2013) ALDH1 
immunohistochemical expression and its significance in salivary 
adenoid cystic carcinoma. Head Neck 35(4):575–578. https ://doi.
org/10.1002/hed.23003 
 24. Sun S, Wang Z (2010) ALDH high adenoid cystic carcinoma cells 
display cancer stem cell properties and are responsible for mediat-
ing metastasis. Biochem Biophys Res Commun 369(4):843–848. 
https ://doi.org/10.1016/j.bbrc.2010.04.170
 25. Chang B, Liu G, Xue F, Rosen D, Xiao L, Wang X, Liu J (2009) 
ALDH1 expression correlates with favorable prognosis in ovar-
ian cancers. Mod Pathol 22(6):817–823. https ://doi.org/10.1038/
modpa thol.2009.35
 26. Yi C, Li B, Zhou C (2016) Bmi-1 expression predicts prognosis 
in salivary adenoid cystic carcinoma and correlates with epithe-
lial-mesenchymal transition-related factors. Ann Diagn Pathol 
22:38–44
 27. Rodrigues M, Xavier F, Andrade N, Lopes C, Miguita Luiz L, 
Sedassari B, Ibarra A, López R, Kliemann-Schmerling C, Moyses 
R, Tajara da Silva E, Nunes F (2018) Prognostic implications of 
CD44, NANOG, OCT4, and BMI1 expression in tongue squa-
mous cell carcinoma. Head Neck 40(8):1759–1773. https ://doi.
org/10.1002/hed.25158 
 28. Koren A, Rijavec M, Sodja E, Kern I, Sadikov A, Kovac V, 
Korosec P, Cufer T (2017) High BMI1 mRNA expression in 
peripheral whole blood is associated with favorable prognosis 
in advanced non-small cell lung cancer patients. Oncotarget 
8(15):25384–25394. https ://doi.org/10.18632 /oncot arget .15914 
 29. Xu X, Liu Y, Su J, Li D, Hu J, Huang Q, Lu M, Liu X, Ren J, 
Chen W, Sun L (2016) Downregulation of Bmi-1 is associated 
with suppressed tumorigenesis and induced apoptosis in CD44(+) 
nasopharyngeal carcinoma cancer stem-like cells. Oncol Rep 
35(2):923–931. https ://doi.org/10.3892/or.2015.4414
 30. Binmadi N, Elsissi A, Elsissi N (2016) Expression of cell adhesion 
molecule CD44 in mucoepidermoid carcinoma and its association 
with the tumor behavior. Head Face Med 29(12):8. https ://doi.
org/10.1186/s1300 5-016-0102-4
 31. Xu W, Wang Y, Qi X, Xie J, Wei Z, Yin X, Wang Z, Meng J, Han 
W (2017) Prognostic factors of palatal mucoepidermoid carci-
noma: a retrospective analysis based on a double-center study. Sci 
Rep 7:43907. https ://doi.org/10.1038/srep4 3907
 32. Wang Y, Chen W, Huang Z, Yang Z, Zhang B, Wang J, Li H, 
Li J (2011) Expression of the membrane-cytoskeletal linker 
Ezrin in salivary gland adenoid cystic carcinoma. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endod 112(1):96–104. https ://doi.
org/10.1016/j.tripl eo.2011.02.018
 33. Mack B, Gires O (2008) CD44s and CD44v6 expression in 
head and neck epithelia. PLoS ONE 3(10):e3360. https ://doi.
org/10.1371/journ al.pone.00033 60
 34. Ludwig N, Szczepanski M, Gluszko A, Szafarowski T, Azambuja 
J, Dolg L, Gellrich N, Kampmann A, Whiteside T, Zimmerer R 
(2019) CD44(+) tumor cells promote early angiogenesis in head 
and neck squamous cell carcinoma. Cancer Lett 467:85–95. https 
://doi.org/10.1016/j.canle t.2019.10.010
 35. Chai L, Liu H, Zhang Z, Wang F, Wang Q, Zhou S, Wang S (2014) 
CD44 expression is predictive of poor prognosis in pharyngo-
laryngeal cancer: systematic review and meta-analysis. Tohoku J 
Exp Med 232(1):9–19
 36. Rajarajan A, Stokes A, Bloor B, Ceder R, Desai H, Grafström 
R, Odell E (2012) CD44 expression in oro-pharyngeal carci-
noma tissues and cell lines. PLoS ONE 7(1):e28776. https ://doi.
org/10.1371/journ al.pone.00287 76
 37. Park J, Hong D, Park J (2019) Association between morphologi-
cal patterns of myometrial invasion and cancer stem cell mark-
ers in endometrial endometrioid carcinoma. Pathol Oncol Res 
25(1):123–130
 38. Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z, Wang K, Zong 
S (2019) The prognostic and clinical value of CD44 in colo-
rectal cancer: a meta-analysis. Front Oncol 9:309. https ://doi.
org/10.3389/fonc.2019.00309 
 39. Dai W, Tan X, Sun C, Zhou Q (2014) High expression of SOX2 
is associated with poor prognosis in patients with salivary gland 
adenoid cystic carcinoma. Int J Mol Sci 15(5):8393–8406. https 
://doi.org/10.3390/ijms1 50583 93
 40. Sedassari B, Rodrigues M, Conceição T, Mariano F, Alves V, 
Nunes F, Altemani A, de Sousa S (2017) Increased SOX2 expres-
sion in salivary gland carcinoma ex pleomorphic adenoma pro-
gression: an association with adverse outcome. Virchows Arch 
471(6):775–784. https ://doi.org/10.1007/s0042 8-017-2220-1
 41. Neumann J, Bahr F, Horst D, Kriegl L, Engel J, Luque R, Gerhard 
M, Kirchner T, Jung A (2011) SOX2 expression correlates with 
lymph-node metastases and distant spread in right-sided colon 
cancer. BMC Cancer 11:518
 42. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, 
Schneider F, Petersen K, Wallwiener D, Kanz L, Fend F, Perner 
S, Bareiss P, Staebler A (2011) Expression of the embryonic stem 
cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 
https ://doi.org/10.1186/1471-2407-11-42
 43. Medema J (2013) Cancer stem cells: the challenges ahead. Nat 
Cell Biol 15(4):338–344. https ://doi.org/10.1038/ncb27 17
 44. Wang T, Shigdar S, Gantier M, Hou Y, Wang L, Li Y, Sha-
maileh H, Yin W, Zhou S, Zhao X, Duan W (2015) Cancer stem 
cell targeted therapy: progress amid controversies. Oncotarget 
6(42):44191–44206
 45. Hocwald E, Korkmaz H, Yoo G, Adsay V, Shibuya T, Abrams J, 
Jacobs J (2001) Prognostic factors in major salivary gland cancer. 
Laryngoscope 111(8):1434–1439
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
